UK markets open in 2 hours 5 minutes
  • NIKKEI 225

    26,422.20
    +314.55 (+1.20%)
     
  • HANG SENG

    21,498.91
    -87.75 (-0.41%)
     
  • CRUDE OIL

    99.03
    +0.50 (+0.51%)
     
  • GOLD FUTURES

    1,743.30
    +6.80 (+0.39%)
     
  • DOW

    31,037.68
    +69.86 (+0.23%)
     
  • BTC-GBP

    17,073.22
    +147.91 (+0.87%)
     
  • CMC Crypto 200

    443.59
    +8.06 (+1.85%)
     
  • ^IXIC

    11,361.85
    +39.61 (+0.35%)
     
  • ^FTAS

    3,910.80
    +46.89 (+1.21%)
     

Global Viral Vector Manufacturing Market to Reach $1.2 Billion by 2026

·28-min read
ReportLinker
ReportLinker

Abstract: What`s New for 2022? -Global competitiveness and key competitor percentage market shares. -Market presence across multiple geographies - Strong/Active/Niche/Trivial.

New York, June 23, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Viral Vector Manufacturing Industry" - https://www.reportlinker.com/p05799925/?utm_source=GNW
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year

Global Viral Vector Manufacturing Market to Reach $1.2 Billion by 2026

Viral vectors are tools that find common usage in molecular biology related research, for the main purpose of delivering genetic materials to cells. The process of delivery is performed in vivo or inside the living organism and also in vitro or within cell culture. Viruses were able to evolve distinct molecular mechanisms which allow effective transmission of their genomes in the cells that they infect. The process of genetic material or genes delivery using a vector is called transduction. The cells that are infected are referred to as the transduced. Viral vectors were used by molecular biologists as early as in the 70s. SV40, a modified virus with DNA from bacteriophage ?, was used for infecting cells in monkey kidney. Viral vectors are currently being used for vaccines development and gene therapy in addition to their use in molecular biology. Though viral vectors are generally customized to suit specific applications, they have certain common properties in terms of safety, stability, toxicity, cell type specificity and identification. Usually, viral vectors are derived from viruses that are pathogenic. Modification is done to minimize risks while handling. Modification involves elimination of a viral genome part that is important for the replication of the virus. A modified virus requires helpers to produce new versions and therefore only effective for so long as to infect the cells. Another important property of viral vectors is that they are of low toxicity, having limited impact on cell physiology. Also, certain viruses are unstable genetically. They rearrange genomes rapidly which can be damaging to reproducibility and predictability of work done using viral vectors.

Amid the COVID-19 crisis, the global market for Viral Vector Manufacturing estimated at US$450.5 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2026, growing at a CAGR of 18.5% over the analysis period. Retroviral Vectors, one of the segments analyzed in the report, is projected to record a 18.5% CAGR and reach US$547.1 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Adenoviral Vectors segment is readjusted to a revised 18.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $327.6 Million in 2021, While China is Forecast to Reach $49 Million by 2026

The Viral Vector Manufacturing market in the U.S. is estimated at US$327.6 Million in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$49 Million by the year 2026 trailing a CAGR of 21.9% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.8% and 16% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.

The increasing prevalence of various genetic disorders and target diseases such as infectious diseases, increased funding availability for development of gene therapy, research efforts in the field of viral vector based cell and gene therapies, and increasing efficacy of viral vectors in delivering gene therapy are fueling growth in the global viral vectors manufacturing market. The growing investments into biopharmaceutical production, rising healthcare spending, technology advancements and healthcare needs of aging population are fueling growth in the viral vectors market. Rise in number of clinical studies, and potential applications in novel drug delivery approaches are also fueling growth in the market. Several viral vector-based drugs have already been approved including Gendicine™, which is the foremost gene therapy drug based on oncolytic adenovirus vector; StrimvelisR, a lentivirus vector for severe combined immunodeficiency (SCID); GlyberaRR, a recombinant AAV for addressing lipoprotein lipase deficiency.

Adeno-Associated Viral Vectors Segment to Reach $287.8 Million by 2026

AAVs or adeno-associated viruses are those that infect primate species and humans commonly. Even though they do not cause major diseases and only result in a minor immune response, the viruses are able to infect non-dividing as well as dividing cells and incorporate virus genome into host cell. AAV also stays in the form of episomal mostly, performing stable and long expression - features which make the viruses attractive candidates for viral vectors` creation, to be used in gene therapy. In the global Adeno-associated Viral Vectors segment, USA, Canada, Japan, China and Europe will drive the 19.7% CAGR estimated for this segment. These regional markets accounted for a combined market size of US$89.5 Million in the year 2020. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$8.2 Million by the year 2026.
Select Competitors (Total 80 Featured) -

  • Batavia Biosciences B.V.

  • BioNTech IMFS GmbH

  • Cobra Biologics Ltd.

  • FinVector Oy

  • FUJIFILM Diosynth Biotechnologies

  • Genelux Corporation

  • Kaneka Eurogentec S.A.

  • Lonza Group AG

  • MaxCyte, Inc.

  • Merck KGaA

  • Novasep Inc.

  • Oxford BioMedica plc

  • Sirion-Biotech GmbH

  • Spark Therapeutics, Inc.

  • Thermo Fisher Scientific Inc.

  • Vector Biolabs

  • Vigene Biosciences, Inc.

  • Virovek, Inc.




Read the full report: https://www.reportlinker.com/p05799925/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of COVID-19 Pandemic and Looming Global Recession
With Viral Vector-based Vaccines Used for COVID-19 in
Development, Viral Vector Manufacturing Market Poised to
Benefit
An Introduction to Viral Vector Manufacturing
Applications of Viral Vectors
Types of Viral Vectors
Global Viral Vector Manufacturing Market: Prospects & Outlook
Competition
COVID-19 Pandemic Puts Pressure on Already Constrained Viral
Vector Manufacturing Capacity
A Glance at Select Investments in Expanding Viral Vector
Manufacturing Capacity
Recent Market Activity
Viral Vector Manufacturing - Global Key Competitors Percentage
Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Infectious Diseases, Genetic Disorders &
Cancers Drives Market
Global Aging Population Statistics for the 65+ Age Group in
Million by Geographic Region for the Years 2019, 2025, 2035
and 2050
Elderly Population (65+ Years) as a % of Total Population by
Developed, Less Developed and Least Developed Regions: 2019 &
2030
Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-
2025) & (2045-2050)
Gene Therapy Emerges as a Major Therapeutic Approach for
Inheritable and Acquired Diseases, Spurring Market Prospects
Gene Therapy Set to Witness Rapid Growth Post COVID-19
Viral Vectors Lead the Gene Therapy Market
Adeno-Associated Virus Vectors: A Leading Platform for Gene
Therapy
Lentiviral Vectors Witness Increased Interest for Gene Therapy
Funding Support for Gene Therapy Development Presents Market
Opportunities
Complexity in Viral Vector Production for Gene therapies
Amidst Rising Cancer Incidence, Focus on Viral Vector-based
Gene Therapies to Boost Market
Global Cancer Incidence: Number of New Cancer Cases in Million
for the Years 2018, 2020, 2025, 2030, 2035 and 2040
Global Number of New Cancer Cases and Cancer-related Deaths by
Cancer Site for 2018
Number of New Cancer Cases and Deaths (in Million) by Region
for 2018
Engineered and Natural Oncolytic Viral Vectors: A Key
Development in Viral Vector-based Cancer Therapy
Growing Threat Posed by Infectious Diseases Drives Focus onto
Vector Viral-based Therapies & Vaccines
Infectious Diseases Remain Major Cause of Death in Under
Developed Regions: Breakdown of Leading Causes of Death in
Sub-Saharan Africa (in %)
Infectious Diseases Related Mortality High Among Children Below
5 Years: Breakdown of Leading Causes of Death in Children
Below 5 Years (in %)
Rising Significance of Viral Vectors in New Vaccine Development
Adenovirus-based Vaccines: Evolution Over the Years
Viral Vector Emerges as a Next-Gen Platform for COVID-19
Vaccines Development
Rush to Develop and Rollout COVID-19 Vaccines Boosts Prospects
for Viral Vector Manufacturing
COVID-19 Vaccines Under Development
Vaccines in Pipeline by Technology
Vaccine Technologies in Pre-Clinical Studies
Replicating and Non-Replicating Viral Vector-Based Vaccines
Non-Replicating Viral vector Vaccine in Clinical Development:
As on December 2nd, 2020
Replicating Viral vector Vaccine Candidate in Clinical
Development: As on December 2nd, 2020
Adenoviral Vectors: Frontrunners of New Vaccine for COVID-19
Vaccines for COVID-19 Confronts Logistic Obstacles to Overcome
Market to Benefit from the Emergence of New Technologies to
Manufacture Viral Vectors
New Trends for Optimizing Workflow Using Viral Vectors
Production Workflow & Viral Vectors
Closed-System-Adherent Culture of Cells: Recent Advances
Limitations in Viral Vector Manufacturing Impact Market
Innovations & Collaborations: Essential to Resolve Challenges
Facing Large-Scale GMP Viral Vector Manufacturing

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Viral
Vector Manufacturing by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Viral Vector Manufacturing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 3: World 11-Year Perspective for Viral Vector
Manufacturing by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2016, 2021 &
2027

Table 4: World Recent Past, Current & Future Analysis for
Retroviral Vectors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Retroviral Vectors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 6: World 11-Year Perspective for Retroviral Vectors by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2016, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Adenoviral Vectors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Adenoviral Vectors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 9: World 11-Year Perspective for Adenoviral Vectors by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2016, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Adeno-associated Viral Vectors by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Adeno-associated Viral
Vectors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2016
through 2019 and % CAGR

Table 12: World 11-Year Perspective for Adeno-associated Viral
Vectors by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2016, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Other Types by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 14: World Historic Review for Other Types by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 15: World 11-Year Perspective for Other Types by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2016, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 17: World Historic Review for Cancer by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2016 through 2019 and % CAGR

Table 18: World 11-Year Perspective for Cancer by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2016, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Genetic Disorders by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Genetic Disorders by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 21: World 11-Year Perspective for Genetic Disorders by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2016, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Infectious Diseases by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Infectious Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 24: World 11-Year Perspective for Infectious Diseases by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2016, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Other Diseases by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Other Diseases by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 27: World 11-Year Perspective for Other Diseases by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2016, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Pharma & Biopharma Companies by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Pharma & Biopharma
Companies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2016
through 2019 and % CAGR

Table 30: World 11-Year Perspective for Pharma & Biopharma
Companies by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2016, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Research Institutes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Research Institutes by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 33: World 11-Year Perspective for Research Institutes by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2016, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Viral Vector Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United States for 2022
(E)
Table 34: USA Recent Past, Current & Future Analysis for Viral
Vector Manufacturing by Type - Retroviral Vectors, Adenoviral
Vectors, Adeno-associated Viral Vectors and Other Types -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Viral Vector Manufacturing by
Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types Markets - Independent Analysis of
Annual Revenues in US$ Thousand for Years 2016 through 2019
and % CAGR

Table 36: USA 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 37: USA Recent Past, Current & Future Analysis for Viral
Vector Manufacturing by Disease - Cancer, Genetic Disorders,
Infectious Diseases and Other Diseases - Independent Analysis
of Annual Revenues in US$ Thousand for the Years 2020 through
2027 and % CAGR

Table 38: USA Historic Review for Viral Vector Manufacturing by
Disease - Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 39: USA 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 40: USA Recent Past, Current & Future Analysis for Viral
Vector Manufacturing by End-Use - Pharma & Biopharma Companies
and Research Institutes - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 41: USA Historic Review for Viral Vector Manufacturing by
End-Use - Pharma & Biopharma Companies and Research Institutes
Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2016 through 2019 and % CAGR

Table 42: USA 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

CANADA
Table 43: Canada Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Type - Retroviral Vectors,
Adenoviral Vectors, Adeno-associated Viral Vectors and Other
Types - Independent Analysis of Annual Revenues in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Viral Vector Manufacturing
by Type - Retroviral Vectors, Adenoviral Vectors,
Adeno-associated Viral Vectors and Other Types Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2016 through 2019 and % CAGR

Table 45: Canada 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 46: Canada Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Disease - Cancer, Genetic
Disorders, Infectious Diseases and Other Diseases - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 47: Canada Historic Review for Viral Vector Manufacturing
by Disease - Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 48: Canada 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 49: Canada Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by End-Use - Pharma & Biopharma
Companies and Research Institutes - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Canada Historic Review for Viral Vector Manufacturing
by End-Use - Pharma & Biopharma Companies and Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 51: Canada 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

JAPAN
Viral Vector Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Japan for 2022 (E)
Table 52: Japan Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Type - Retroviral Vectors,
Adenoviral Vectors, Adeno-associated Viral Vectors and Other
Types - Independent Analysis of Annual Revenues in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Viral Vector Manufacturing
by Type - Retroviral Vectors, Adenoviral Vectors,
Adeno-associated Viral Vectors and Other Types Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2016 through 2019 and % CAGR

Table 54: Japan 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 55: Japan Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Disease - Cancer, Genetic
Disorders, Infectious Diseases and Other Diseases - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 56: Japan Historic Review for Viral Vector Manufacturing
by Disease - Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 57: Japan 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 58: Japan Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by End-Use - Pharma & Biopharma
Companies and Research Institutes - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 59: Japan Historic Review for Viral Vector Manufacturing
by End-Use - Pharma & Biopharma Companies and Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 60: Japan 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

CHINA
Viral Vector Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in China for 2022 (E)
Table 61: China Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Type - Retroviral Vectors,
Adenoviral Vectors, Adeno-associated Viral Vectors and Other
Types - Independent Analysis of Annual Revenues in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Viral Vector Manufacturing
by Type - Retroviral Vectors, Adenoviral Vectors,
Adeno-associated Viral Vectors and Other Types Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2016 through 2019 and % CAGR

Table 63: China 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 64: China Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Disease - Cancer, Genetic
Disorders, Infectious Diseases and Other Diseases - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 65: China Historic Review for Viral Vector Manufacturing
by Disease - Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 66: China 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 67: China Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by End-Use - Pharma & Biopharma
Companies and Research Institutes - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: China Historic Review for Viral Vector Manufacturing
by End-Use - Pharma & Biopharma Companies and Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 69: China 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

EUROPE
Viral Vector Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Europe for 2022 (E)
Table 70: Europe Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 71: Europe Historic Review for Viral Vector Manufacturing
by Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2016 through 2019 and % CAGR

Table 72: Europe 11-Year Perspective for Viral Vector
Manufacturing by Geographic Region - Percentage Breakdown of
Value Revenues for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2016, 2021 & 2027

Table 73: Europe Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Type - Retroviral Vectors,
Adenoviral Vectors, Adeno-associated Viral Vectors and Other
Types - Independent Analysis of Annual Revenues in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Viral Vector Manufacturing
by Type - Retroviral Vectors, Adenoviral Vectors,
Adeno-associated Viral Vectors and Other Types Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2016 through 2019 and % CAGR

Table 75: Europe 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 76: Europe Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Disease - Cancer, Genetic
Disorders, Infectious Diseases and Other Diseases - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 77: Europe Historic Review for Viral Vector Manufacturing
by Disease - Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 78: Europe 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 79: Europe Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by End-Use - Pharma & Biopharma
Companies and Research Institutes - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: Europe Historic Review for Viral Vector Manufacturing
by End-Use - Pharma & Biopharma Companies and Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 81: Europe 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

FRANCE
Viral Vector Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in France for 2022 (E)
Table 82: France Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Type - Retroviral Vectors,
Adenoviral Vectors, Adeno-associated Viral Vectors and Other
Types - Independent Analysis of Annual Revenues in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Viral Vector Manufacturing
by Type - Retroviral Vectors, Adenoviral Vectors,
Adeno-associated Viral Vectors and Other Types Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2016 through 2019 and % CAGR

Table 84: France 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 85: France Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Disease - Cancer, Genetic
Disorders, Infectious Diseases and Other Diseases - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 86: France Historic Review for Viral Vector Manufacturing
by Disease - Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 87: France 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 88: France Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by End-Use - Pharma & Biopharma
Companies and Research Institutes - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 89: France Historic Review for Viral Vector Manufacturing
by End-Use - Pharma & Biopharma Companies and Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 90: France 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

GERMANY
Viral Vector Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in Germany for 2022 (E)
Table 91: Germany Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Type - Retroviral Vectors,
Adenoviral Vectors, Adeno-associated Viral Vectors and Other
Types - Independent Analysis of Annual Revenues in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Viral Vector
Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors,
Adeno-associated Viral Vectors and Other Types Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2016 through 2019 and % CAGR

Table 93: Germany 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 94: Germany Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Disease - Cancer, Genetic
Disorders, Infectious Diseases and Other Diseases - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 95: Germany Historic Review for Viral Vector
Manufacturing by Disease - Cancer, Genetic Disorders,
Infectious Diseases and Other Diseases Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2016
through 2019 and % CAGR

Table 96: Germany 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 97: Germany Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by End-Use - Pharma & Biopharma
Companies and Research Institutes - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 98: Germany Historic Review for Viral Vector
Manufacturing by End-Use - Pharma & Biopharma Companies and
Research Institutes Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 99: Germany 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

ITALY
Table 100: Italy Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Type - Retroviral Vectors,
Adenoviral Vectors, Adeno-associated Viral Vectors and Other
Types - Independent Analysis of Annual Revenues in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Viral Vector Manufacturing
by Type - Retroviral Vectors, Adenoviral Vectors,
Adeno-associated Viral Vectors and Other Types Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2016 through 2019 and % CAGR

Table 102: Italy 11-Year Perspective for Viral Vector
Manufacturing by Type - Percentage Breakdown of Value Revenues
for Retroviral Vectors, Adenoviral Vectors, Adeno-associated
Viral Vectors and Other Types for the Years 2016, 2021 & 2027

Table 103: Italy Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by Disease - Cancer, Genetic
Disorders, Infectious Diseases and Other Diseases - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 104: Italy Historic Review for Viral Vector Manufacturing
by Disease - Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2016 through 2019 and % CAGR

Table 105: Italy 11-Year Perspective for Viral Vector
Manufacturing by Disease - Percentage Breakdown of Value
Revenues for Cancer, Genetic Disorders, Infectious Diseases and
Other Diseases for the Years 2016, 2021 & 2027

Table 106: Italy Recent Past, Current & Future Analysis for
Viral Vector Manufacturing by End-Use - Pharma & Biopharma
Companies and Research Institutes - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 107: Italy Historic Review for Viral Vector Manufacturing
by End-Use - Pharma & Biopharma Companies and Research
Institutes Markets - Independent Analysis of Annual Revenues in
US$ Thousand for Years 2016 through 2019 and % CAGR

Table 108: Italy 11-Year Perspective for Viral Vector
Manufacturing by End-Use - Percentage Breakdown of Value
Revenues for Pharma & Biopharma Companies and Research
Institutes for the Years 2016, 2021 & 2027

UNITED KINGDOM
Viral Vector Manufacturing Market Presence - Strong/Active/
Niche/Trivial - Key Competitors in the United Kingdom for 2022
(E)
Table 109: UK Recent Past, Current & Future Analysis for Viral
Vector Manufacturing by Type - Retroviral Vectors, Adenoviral

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05799925/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting